Masimo has been granted FDA approval for its breakthrough noninvasive and continuous total hemoglobin monitoring technology (SpHb). The technology should make hemoglobin measurement more convenient and available to clinicians in hospital and outpatient settings, according to the company. It is designed to improve patient safety and decrease costs. Noninvasive total hemoglobin monitoring will be offered as part of the upgradable Masimo Rainbow SET technology platform. The company expects the technology to be available to select customers by the third quarter of this year.

GlaxoSmithKline PLC has launched a new treatment for Parkinson’s disease (PD) in the U.K. ReQuip XL® (ropinirole prolonged-release tablets) is the U.K.’s first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD1, providing continuous delivery of ropinirole from a single daily dose. Ropinirole prolonged-release is approved for the treatment of idiopathic Parkinson’s disease (Monotherapy and Adjunct Therapy) in patients already taking ropinirole immediate release tablets and in whom adequate symptomatic control has been established.